EP3606534B1 - Phospholipid derivatives and their use as medicaments - Google Patents

Phospholipid derivatives and their use as medicaments Download PDF

Info

Publication number
EP3606534B1
EP3606534B1 EP18719029.3A EP18719029A EP3606534B1 EP 3606534 B1 EP3606534 B1 EP 3606534B1 EP 18719029 A EP18719029 A EP 18719029A EP 3606534 B1 EP3606534 B1 EP 3606534B1
Authority
EP
European Patent Office
Prior art keywords
acyl
dapl
mixture
use according
lysophosphatidyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP18719029.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3606534A1 (en
Inventor
Michal Dvorak
Marta DVORAKOVA
Vit Karafiat
Jan Stursa
Lukas Werner
Lucie JANECKOVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smart Brain sro
Institute of Molecular Genetics CAS
Original Assignee
Smart Brain SRO
Institute of Molecular Genetics CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smart Brain SRO, Institute of Molecular Genetics CAS filed Critical Smart Brain SRO
Priority to PL18719029T priority Critical patent/PL3606534T3/pl
Publication of EP3606534A1 publication Critical patent/EP3606534A1/en
Application granted granted Critical
Publication of EP3606534B1 publication Critical patent/EP3606534B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/113—Esters of phosphoric acids with unsaturated acyclic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin

Definitions

  • the present invention relates to lysophospholipid-based compounds, and to their use as medicaments.
  • Phospholipids are a key component of all biological membranes - they form the basis of the membrane bilayer together with proteins, glycolipids and cholesterol derivatives. They confer on the membranes their specific semi-permeable properties. Lipids from hen egg yolks contain a significant amount (20 %) of phospholipids. Dominant phospholipids of the egg yolk are phosphatidylcholine (75 %) and phosphatidylethanolamine (20 % of all egg yolk phospholipids). Furthermore, the yolks contain small amounts of phosphatidylserine, phosphatidylinositol, phosphatidic acid, sphingomyelin and others in trace amounts.
  • the lipids Upon eating food, the lipids are emulsified in the intestine with bile salts, absorbed and processed by intestinal lining cells, enterocytes.
  • the first step in the digestion of phospholipids is their cleavage with phospholipase A2, which is secreted by small intestine enterocytes, to form lysophospholipids and free fatty acids.
  • phospholipase A2 which is secreted by small intestine enterocytes, to form lysophospholipids and free fatty acids.
  • enterocytes metabolized and incorporated into lipoprotein particles (e.g., chylomicrons) which serve as vehicles for transporting these substances through the lymphatic system and bloodstream to the cells of other tissues.
  • lipoprotein particles e.g., chylomicrons
  • Glycerol-based lysophospholipids occur in organisms not only as intermediates in the synthesis of various phospholipids, but, as has been shown recently, also have their own significant regulatory functions. There is hardly any information about the biological activity of 1-acyl lysophosphatidylcholine or of a mixture of 1-acyl lysophospholipids prepared from a natural mixture of phospholipids using phospholipase A2 and about their possible therapeutic use. It appears that 1-acyl lysoPC is indirectly involved in organ regeneration and wound healing (1, 2) and may possibly be used to treat autoimmune and degenerative diseases (3-7), and perhaps could be useful in the treatment of diabetes (8, 9).
  • lysophosphatidylcholine In blood serum, lysophosphatidylcholine is the most abundant lysophospholipid. It is a substrate for the enzyme autotaxin. In body fluids, autotaxin, which is a phospholipase D, cleaves choline group from lysophosphatidylcholine to form lysophosphatidic acid (LPA).
  • LPA is a relatively well-studied substance due to its significant biological effects. LPA activates cell proliferation and angiogenesis and has pro-inflammatory and pro-tumor effects. Signaling pathways controlled by this acid through LPA receptors play a major role in carcinogenesis, tumor cell invasiveness and metastatic potential. The LPA signaling appears to be involved in the resistance of some types of cancer towards therapy (10-12).
  • 1-acyl lysophosphatidylcholine due to its conversion to a pro-tumor LPA, will exhibit pro-tumor effects in vivo
  • the present invention relates to 1-acyl-lysophosphatidyl derivatives of general formula I, wherein
  • R is selected from the group consisting of C5 to C10 linear, branched or cyclic or cycle-containing alkyl or alkenyl, such as pentyl or 3,5,5-trimethylpentyl, cyclopentylethyl; or C13 to C30, preferably C13 to C20 linear or branched alkyl or alkenyl, in particular C15, C16, C17, C18 or C19 linear alkyl or alkenyl.
  • Alkenyls contain one or more double bonds.
  • R2 is selected from the group consisting of C10-C30, preferably C10-C20 acyls contaning linear saturated or unsaturated chains, such as decanoyl, palmitoyl, stearoyl, oleoyl, linoleoyl, elaidoyl.
  • Suitable counterions include alkali metal cations, halogen anions, or anions derived from inorganic or organic acids.
  • the charge can be compensated for by formation of an internal salt - betaine.
  • the nitrogen atom carries a positive charge when R3 is present.
  • At least one of R1, R2, R3 is methyl. In one particular embodiment, R1, R2 and R3 are methyls.
  • R1 and R2 are H, and R3 is not present.
  • R1 is H and R2 is C10-C20 acyl containing linear saturated or unsaturated chains, and R3 is not present.
  • the compounds of the present invention show cytotoxic effects on tumor cells, thus suppressing the growth of tumor cells.
  • the object of the present invention is therefore the compounds of general formula (I) for use in the treatment of cancer selected from melanoma and hepatocarcinoma. It has been shown within the framework of the present invention that the compounds of the general formula (I) are potent inhibitors of the growth of various tumor cells in tissue culture as well as inhibitors of the growth of experimental tumors in animal models.
  • the compounds of formula (I) may be prepared by selective deacylation of the respective phospholipids, optionally modified phospholipids.
  • Starting phospholipids may include phosphatidylcholines, phosphatidylethanolamines, their derivatives by substitution on a nitrogen atom, or natural mixtures of phospholipids, optionally modified by substitution on a nitrogen atom.
  • Natural mixtures of phospholipids may include, for example, egg yolk phospholipids.
  • Selective deacylation can be accomplished by synthetic procedures known to those skilled in the art or enzymatically.
  • a subsequent acylation can also be performed to provide a compound carrying the desired acyl radical R.
  • the acylation carried out after deacylation must be selective - this can be achieved, for example, by protecting the -OH group by protecting groups well known to those skilled in the art.
  • the compound of formula I can be isolated after deacylation from the reaction mixture either alone or in admixture with the free fatty acid.
  • the presence of fatty acid does not influence the cytotoxic effects of the compounds of formula I.
  • the object of the present invention is furthermore a pharmaceutical composition
  • a pharmaceutical composition comprising at least one compound of general formula (I) and at least one carrier, diluent or filler.
  • the pharmaceutical composition may further contain other suitable auxiliaries such as lubricants, tabletting-facilitating agents, emulsifiers, coatings, etc.
  • the pharmaceutical composition may be in the form, for example, of capsules, tablets, ointments, creams, suspensions, emulsions, solutions. It may be preferably in a form destined for oral or intravenous administration.
  • a further object of the present invention is at least one 1-acyl-lysophosphatidyl derivative of general formula (I) for use in a method of treatment of cancer selected from a hepatocarcinoma and a melanoma, wherein further an anticancer drug is administered.
  • the cancer is a solid tumor, selected from a hepatocarcinoma, or a melanoma.
  • the anticancer drug is doxorubicin.
  • the co-administration of the 1-acyl-lysophosphatidyl derivative of formula (I) with an anticancer drug leads to dose reduction of the anticancer drug and thereby to increasing efficacy while decreasing the toxicity of the drug and the unwanted side effects of the anticancer drugs.
  • the co-administration of the 1-acyl-lysophosphatidyl derivative of formula (I) with an anticancer drug is preferably performed in the ratio of at least 20:1, preferably at least 50:1, more preferably at least 100:1, even more preferably at least 180:1 or at least 200:1.
  • the substances can be administered together or within 12 hours of each other, preferably within 6 hours of each other, more preferably 2 hours of each other.
  • Example 1 Isolation of naturally occurring mixture of phospholipids from egg yolks
  • the precipitate was washed three times with n-hexane:acetone (1:2) and dried in a desiccator under reduced pressure.
  • the thus purified phospholipids were used either to isolate phosphatidylcholine and phosphatidylethanolamine or to prepare a mixture of lysophospholipids.
  • the phospholipid content was determined by measuring the amount of phosphorus.
  • Example 2 Isolation of phosphatidylcholine (PC) and phosphatidylethanolamine (PE)
  • the combined fractions containing either PE or PC were evaporated and used to prepare 1-acyl-lysophosphatidylethanolamine (1-acyl-lysoPE), 1-acyl lysophosphatidylcholine (1-acyl- lysoPC) and N-acyl-lysophosphatidylethanolamines.
  • 1-acyl-lysophosphatidylethanolamine (1-acyl-lysoPE)
  • 1-acyl lysophosphatidylcholine (1-acyl- lysoPC)
  • N-acyl-lysophosphatidylethanolamines 1-acyl-lysophosphatidylethanolamine
  • Small aliquots of the combined PE and PC fractions were analyzed using MALDI-TOF, NMR and TLC along with the standards. These methods verified that the fractions contain practically only PE or PC.
  • R' acyl mixture, major component is palmitoyl PE purified by flash chromatography or PE purchased from Sigma Aldrich at 10% (w/v) concentration were repeatedly vortexed and sonicated at 43 °C in 50 mM Tris-HCl (pH 8.0, 50 mM KCl, 8 mM CaCl 2 ) until the phospholipids were completely dispersed. The phospholipids were then digested with phospholipase A2 (EC 3.1.1.4) at a ratio of 2 units of enzyme/mg phospholipid at 43 °C and the reaction was monitored by silica gel thin layer chromatography (TLC), eluted with chloroform:methanol:water 20:10:1.
  • TLC silica gel thin layer chromatography
  • R' acyl mixture, major component is palmitoyl PC purified by flash chromatography at 10% (w/v) concentration was repeatedly vortexed and sonicated at 43 °C in 50 mM Tris-HCl (pH 8.0, 50 mM KCl, 8 mM CaCl 2 ) until the phospholipids were completely dispergated. PC was then digested with phospholipase A2 at a ratio of 2 units of enzyme/mg phospholipid at 43 °C and the reaction was monitored by silica gel thin layer chromatography (TLC), eluted with chloroform:methanol: water 20:10:1.
  • TLC silica gel thin layer chromatography
  • Method A Total purified phospholipids of Example 1 at 10% (w/v) concentration were repeatedly vortexed and sonicated at 43 ° C in 50 mM Tris.HCl, pH 8.0, 50 mM KCl, 8 mM CaCl 2 until the phospholipids were perfectly dispergated. The phospholipids were then digested with phospholipase A2 at a ratio of 2 units of enzyme/mg phospholipid at 43 °C and the reaction was monitored by TLC, eluted with 20:10:1 chloroform:methanol:water mixture. After complete cleavage, the reaction was stopped by the addition of EDTA to a concentration of 10 mM and stored for a short time at 0-4 ° C.
  • Method B Dried total purified phospholipids of Example 1 were repeatedly vortexed and sonicated at 43 °C in 83 mM sodium deoxycholate in 50 mM Tris.Cl, pH 8.0, 50 mM KCl, 8 mM CaCl 2 . The final concentration of phospholipids was also 83 mM (relative to PC). Phospholipids were then digested with phospholipase A2 at a rate of 0.2 units of enzyme/mg phospholipids at 43 °C, and the reaction was monitored by TLC eluted with 20:10:1 chloroform:methanol:water mixture.
  • the mixture E-DAPL+FA contains in particular 1-acyl-lysoPC and 1-acyl-lysoPE, which can be characterized by the formulas shown below, wherein R is mostly palmitic acid.
  • the mixture also contains the fatty acid released from the enzymatic cleavage, mostly oleic acid.
  • R" acyl mixture, major component is oleoyl
  • major component is oleoyl
  • the PC in 10% (w/v) concentration was repeatedly vortexed and sonicated at 43 °C in 50 mM Tris.HCl, pH 8.0, 50 mM KCl, 8 mM CaCl 2 until it was completely dispergated.
  • the PC was then digested with phospholipase A1 in a ratio of 2 enzyme units/mg of phospholipids at 37 °C, and the reaction was monitored by TLC, eluted with 20:10:1 chloroform:methanol:water mixture.
  • Example 6 From the phosphatidylcholine isolated according to Example 2, the sn-1 fatty acid residue of Example 6 was enzymatically removed, which was replaced by the acyl radical R' (see table below) with an organic esterification reaction.
  • the starting 2-acyl-lysophosphatidylcholine from Example 6 (1 eq) was dissolved in dry dichloromethane (0.06 M), the solution was cooled to 4 °C, and the appropriate fatty acid (hexanoic, stearic, trimethylhexanoic, cyclopentanepropionic) chloride (3 eq).
  • the reaction mixture was further heated to 10 °C and then pyridine (5 eq) and a catalytic amount of DMAP (0.05 eq) were slowly added dropwise. The mixture was stirred overnight at room temperature. The course of the reaction was monitored by TLC (CHCl 3 /MeOH/H 2 O in a ratio of 75/22.5/2.5). The reaction was quenched by extracting the reaction mixture in 50% aqueous NaCl and dichloromethane. The final product was obtained by column chromatography on silica gel (20% (MeOH + 10% H 2 O) in chloroform, + 1% per minute). The resulting product is contaminated with the acylation product of 1-acyl-lysophosphatidylcholine (15-20%) resulting from the transacylation mechanism as a by-product of Example 6.
  • R" acyl mixture, major component is oleoyl 1-stearoyl-phosphatidylcholine was prepared by the procedure described in Example 7, in the yield of 54 %.
  • R" acyl mixture, major component is oleoyl 1-trimethylhexanoyl-phosphatidylcholine was prepared by the procedure described in Example 7, in the yield of 82 %.
  • R" acyl mixture, major component is oleoyl 1-cyclopentanepropionyl-phosphatidylcholine was prepared by the procedure described in Example 7, in the yield of 71 %.
  • R" acyl mixture, major component is oleoyl 1-palmitoyl-phosphatidylcholine was prepared by the procedure described in Example 7, in the yield of 15%.
  • 1-acyl-specific 1,2-diacylphospholipids shown in examples 8-12 were digested by phospholipase A2 and purified as described in Example 4. This process yielded the following products which were designated as shown in the following table: R' Designation hexanoyl sn-1 hexanoyl PC/E-DAPL+FA stearoyl sn-1 stearoyl PC/E-DAPL+FA trimethylhexanoyl sn-1 trimethylhexanoyl PC/E-DAPL+FA cyclopentanepropionyl sn-1 cyclopentanepropionyl PC/E-DAPL+FA palmitoyl sn-1 palmitoyl PC/E-DAPL+FA
  • phosphatidylethanolamine isolated according to Example 2 the amino group hydrogen was replaced by the acyl radical R2 (see table below) using an esterification reaction.
  • Phosphatidylethanolamine isolated from the natural source according to Example 2 carries in the sn-1 position a mixture of fatty acid residues, about 80 % being palmitic acid residues, the rest being residues of stearic acid, oleic acid, and a small amount of other fatty acid residues.
  • Purified phosphatidylethanolamine was dissolved in anhydrous benzene and mixed with two equivalents of anhydride (palmitic, decanoic, oleic, linoleic or elaidic, respectively) in the presence of DMAP.
  • the anhydrides were prepared by condensation of the relevant acids in the presence of DCC.
  • the N-acylation was carried out for 30 minutes at room temperature.
  • the reaction mixture was dried, dissolved in hexane, the insoluble fraction was removed by centrifugation, and the N-acyl phosphatidylethanolamines were isolated by precipitation by 2 volume equivalents of acetone at 4 °C overnight.
  • the precipitate was washed 3 times with ice cold hexane:acetone 1:2 at 0 °C.
  • R' acyl mixture
  • major component is palmitoyl
  • R" acyl mixture
  • major component is oleoyl N-decanoyl-phosphatidylethanolamine was prepared by the procedure described in Example 13.
  • R' acyl mixture
  • major component is palmitoyl
  • R" acyl mixture
  • major component is oleoyl N-oleoyl-phosphatidylethanolamine was prepared by the procedure described in Example 13.
  • R' acyl mixture
  • major component is palmitoyl
  • R" acyl mixture
  • major component is oleoyl N-linoleoyl-phosphatidylethanolamine was prepared by the procedure described in Example 13.
  • R' acyl mixture
  • major component is palmitoyl
  • R" acyl mixture
  • major component is oleoyl N-elaidoyl-phosphatidylethanolamine was prepared by the procedure described in Example 13.
  • Example 19 Preparation of 1-acyl-lysophospholipids derived from N-palmitoyl PE, N-decanoyl PE, N-oleoyl PE, N-linoleoyl PE and N-elaidoyl PE, in a mixture with free (cleaved) fatty acid
  • N-acyl phospholipid at 10% (w/v) concentration was repeatedly vortexed and sonicated at 43 °C in 50 mM Tris-HCl (pH 8.0, 50 mM KCl, 8 mM CaCl 2 ) until the phospholipid was completely dispergated, and then it was processed as described in Example 4 - digested by phospholipase A2 at a ratio of 2 units of enzyme/mg phospholipid at 43 °C and the reaction was monitored by silica gel thin layer chromatography (TLC), eluted with chloroform:methanol: water 20:10:1.
  • TLC silica gel thin layer chromatography
  • the 1-acyl-lysophospholipid products prepared according to the present examples by enzymatic deacylation at sn-2 position to form a mixture with fatty acids i.e., PE/E-DAPL+FA, PC/E-DAPL+FA and E-DAPL+FA, sn-1 hexanoyl PC/E-DAPL+FA, sn-1 stearoyl PC/E-DAPL+FA, sn-1 trimethylhexanoyl PC/E-DAPL+FA, sn-1 cyclopentanepropionyl PC/E-DAPL+FA, N-palmitoyl PE/E-DAPL+FA, N-decanoyl PE/E-DAPL+FA, N-oleoyl PE/E-DAPL+FA, N-linoleoyl PE/E-DAPL+FA, N-elaidoyl PE/E-DAPL+FA) were dissolved in ethanol, and then water and chloroform were gradually added to
  • the dried formulations were practically free of fatty acids and were designated PE/E-DAPL, PC/E-DAPL, E-DAPL, sn-1 hexanoyl PC/E-DAPL, sn-1 stearoyl PC/E-DAPL, sn-1 trimethylhexanoyl PC/E-DAPL, sn-1 cyclopentanepropionyl PC/E-DAPL, N-palmitoyl PE/E-DAPL, N-decanoyl PE/E-DAPL, N-oleoyl PE/E-DAPL, N-linoleoyl PE/E-DAPL and N-elaidoyl PE/E-DAPL.
  • the starting phospholipids were used at the same concentrations and conditions.
  • the starting phospholipids were PE, PC, sn-1 stearoyl PC, N-palmitoyl PE or the initial mixture of phospholipids, respectively.
  • the cytotoxic activity of the products was tested in tumor cell cultures C32 (human melanoma), TIB-75 (inducing murine hepatocarcinoma), LMH (chicken hepatocarcinoma).
  • the presence of free fatty acids did not have any significant effect on the toxicity of the products to the tested tumor cells.
  • the controls - PE, PC, sn-1 stearoyl PC, N-palmitoyl PE or the initial mixture of phospholipids - at exactly the same concentrations did not affect the phenotype or reduce the rate of cell growth.
  • 2-acyl-lysophospholipids prepared from PC, PE and total phospholipids were tested - these products were slightly cytotoxic, they needed about 4-5 times higher concentration to achieve the same level of toxicity as PE/E-DAPL, PC/E-DAPL, E-DAPL and sn-1 stearoyl PC/E-DAPL.
  • the cytotoxicity of the products was quantified by determining the ATP content in the cells and using neutral red intake, and the IC50 ATP and IC50 NR [ ⁇ M] were determined. Both methods provided virtually the same values.
  • the table shows IC50 ATP values.
  • E-DAPL+FA 1-acyl-lysophosphatidyl derivatives
  • E-DAPL+FA were administered perorally to chickens 5 times a week at 40 mg/20 g of chicken weight.
  • Hepatocarcinomas were induced in the chickens in the embryonic stage by injection of LMH hepatocarcinoma cells. The experiment was evaluated on the 25th day from hatching of the chickens.
  • Chickens Number of chickens in the beginning of the experiment Number of chickens surviving on the 25th day infected, non-treated 8 1 (multiple large hepatic carcinomas) infected, treated by E-DAPL+FA 8 4 (3 chickens were free of carcinomas, 1 chicken had 2 small hepatic carcinomas)
  • Subcutaneous tumors were induced in 16 BALB/c mice (8-10 weeks old) by injection of syngeneic TIB-75 cells.
  • 8 mg of E-DAPL in 0.1 ml saline were administered once a week to a group of 8 mice, and 8 mg of control phospholipids (PLs) were administered once a week to a group of 8 mice, the administered products were applied to the developing tumor area.
  • the tumors were dissected, their diameter was measured in three perpendicular directions, and the spherical volumes were calculated from the mean values.
  • the mean volume of such approximated tumors in mice treated with E-DAPL was 30 % of the volume of tumors in mice treated with control PLs.
  • Intraperitoneal tumors were induced in 20 BALB /c mice (8-10 weeks old) by injection of syngeneic TIB-75 cells.
  • a control group of 10 mice was fed for eight weeks low-fat experimental food (Altromin) and a second group was fed the same diet containing 8 mg of E-DAPL per 5 g food.
  • the mice received the experimental food 4 days a week; in the remaining 3 days they received standard food.
  • 2 control mice died of TIB-75 tumors.
  • 2 equal groups of control and treated mice were dissected.
  • the average tumor weight in the treated mice group was 75% of the weight of control tumors. After 2 more weeks the remaining mice were analyzed.
  • the average tumor weight in the treated mice group was now 40% of the tumor weight in the control group.
  • the experiment shows that E-DAPL administered in the diet (perorally) also slows down the growth of experimental intraperitoneal tumors.
  • E-DAPL was added to the mouse feed mixture - 65 mg of E-DAPL/ 5g of the low-fat diet. This amount was approximately consumed by every mouse every day.
  • mice were fed this modified feed mixture 3 days a week from 16 weeks of age (when they had many dozen polyps in the small intestine) until 28 weeks of age (when only the growing adenomas were present in the small intestine).
  • the small intestine was isolated from the 28-week-old mice treated by E-DAPL and from the control mice fed unmodified low-fat diet 3 days a week, and processed to histological preparations.
  • mice Tumor growth in experimental BALB/C mice was induced by subcutaneous injection of syngeneic tumor cells CT26.CL25. Half of the mice were treated with E-DAPL. Two hundred microlitres of 0.3% E-DAPL (in saline containing 20% phosphate-buffered saline) were administered intravenously to every mouse 3 times per week. Control animals were similarly administered saline/20% phosphate-buffered saline. After three weeks, the tumors were harvested and weighed. The weight of the tumors from the treated animals was 42% of the weight of control tumors. The tumors in mice treated with E-DAPL were also of a limited type, even microscopically, in contrast to control tumors, which were markedly unbounded. This further confirms the beneficial effect of E-DAPL on reducing the growth of malignant tumors. Conclusion: Intravenous administration of E-DAPL in saline is well tolerated and significantly inhibits the development of experimental tumors.
  • the potentiation of cytotoxic effect of E-DAPL/Dox combination was evaluated.
  • the dose-effect relationship of individual drugs and E-DAPL/Dox mixture (ratio 202:1 was tested) was determined on mammary gland 4T1 cancer cell line by means of crystal violet assay (three measurements).
  • the linearized Median-Effect Plot of dose response line provided both parameters (IC 50 ; trend line m value) of Median-Effect Equation for individual and combination treatment [ref: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies; Ting-Chao Chou: Pharmacol Rev. 58(3),2006, 621-81 ; Erratum in Pharmacol Rev.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18719029.3A 2017-04-03 2018-03-29 Phospholipid derivatives and their use as medicaments Active EP3606534B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL18719029T PL3606534T3 (pl) 2017-04-03 2018-03-29 Pochodne fosfolipidów i ich zastosowanie jako leki

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2017-190A CZ308596B6 (cs) 2017-04-03 2017-04-03 Deriváty fosfolipidů a jejich použití jako léčiva
PCT/CZ2018/050015 WO2018184604A1 (en) 2017-04-03 2018-03-29 Phospholipid derivatives and their use as medicaments

Publications (2)

Publication Number Publication Date
EP3606534A1 EP3606534A1 (en) 2020-02-12
EP3606534B1 true EP3606534B1 (en) 2021-05-12

Family

ID=73838693

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18719029.3A Active EP3606534B1 (en) 2017-04-03 2018-03-29 Phospholipid derivatives and their use as medicaments

Country Status (11)

Country Link
US (1) US11414443B2 (zh)
EP (1) EP3606534B1 (zh)
CN (1) CN110494143B (zh)
CA (1) CA3058792C (zh)
CZ (1) CZ308596B6 (zh)
DK (1) DK3606534T3 (zh)
ES (1) ES2877647T3 (zh)
HU (1) HUE055171T2 (zh)
PL (1) PL3606534T3 (zh)
PT (1) PT3606534T (zh)
WO (1) WO2018184604A1 (zh)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577446A (en) * 1968-09-09 1971-05-04 American Home Prod Phosphatidylalkanolamine derivatives
DE2642661C2 (de) * 1976-09-22 1984-06-28 A. Nattermann & Cie GmbH, 5000 Köln Acetoin-dialkyl-phosphorsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung
GB2046092B (en) * 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
AT383130B (de) * 1984-05-15 1987-05-25 Chemie Linz Ag Verfahren zur herstellung von an c1 und c2 verschieden substituierten phosphatidylcholinen und phosphatidylethanolaminen ueber die neuen verbindungen 1-0-tritylglycerophosphocholin beziehungsweise (1-0,n-ditrityl)-glycerophosphoethanolamin
IL84387A0 (en) * 1987-11-06 1990-02-09 Rapaport Erich Pharmaceutical compositions containing a substituted phosphatide
KR0157428B1 (ko) * 1989-02-17 1998-11-16 알렌 불룸 비 전달용 지질부형제와 그 사용법
US5149527A (en) * 1990-09-18 1992-09-22 Oncotech, Inc. Immunopotentiating protocol for chemotherapy-responsive tumors
CZ282139B6 (cs) * 1995-04-03 1997-05-14 Jindřich Rndr. Drsc. Kára Způsob výroby přípravku s dieteticko-preventivním a léčebným účinkem na bázi vaječných l-O-alkyl-2-acyl-fosfatidylethanolaminů
WO2001058910A2 (en) * 2000-02-10 2001-08-16 Liplasome Pharma A/S Lipid-based drug delivery systems
IL142952A (en) * 2001-05-03 2005-12-18 Enzmotec Ltd Process for enzyme-catalyzed production of 1,2 diacylated phospholipids
DE10142014B4 (de) * 2001-08-28 2004-11-11 Degussa Bioactives Deutschland Gmbh & Co. Kg Verfahren zur Herstellung von Phosphatidylserin
KR20050061400A (ko) * 2002-06-20 2005-06-22 아이씨 벡 리미티드 황-함유 인지질 유도체
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
GB201509934D0 (en) * 2015-06-08 2015-07-22 King S College London Nanoparticles
CN105878260A (zh) * 2016-04-29 2016-08-24 陈西敬 一种抗坏血酸棕榈酸酯和阿霉素的组合物脂质体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
PT3606534T (pt) 2021-07-16
ES2877647T3 (es) 2021-11-17
US11414443B2 (en) 2022-08-16
US20200102333A1 (en) 2020-04-02
CA3058792C (en) 2022-08-16
DK3606534T3 (da) 2021-07-12
HUE055171T2 (hu) 2021-11-29
CZ2017190A3 (cs) 2018-10-10
CA3058792A1 (en) 2018-10-11
WO2018184604A1 (en) 2018-10-11
CZ308596B6 (cs) 2020-12-23
CN110494143A (zh) 2019-11-22
PL3606534T3 (pl) 2021-12-13
CN110494143B (zh) 2022-12-20
EP3606534A1 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
Sahara et al. In vivo anti-tumour effect of 3'-sulphonoquinovosyl 1'-monoacylglyceride isolated from sea urchin (Strongylocentrotus intermedius) intestine
AU2007266983B2 (en) Use of phytate as agent inhibiting dissolution of crystals of calcium salts for the prevention of osteoporosis
JPH06293785A (ja) 不飽和脂肪酸含有リン脂質
Berkovic Cytotoxic etherphospholipid analogues
US20120116104A1 (en) Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species
CN107001980A (zh) 醚磷脂及其制备方法
WO2012177100A2 (en) Composition comprising phosphatidylcholine as an active ingredient for attenuating toxicity of anticancer agent
JP4163007B2 (ja) カルバ環状ホスファチジン酸誘導体を含む癌転移抑制剤
Zaremberg et al. Lipids and membrane microdomains: the glycerolipid and alkylphosphocholine class of cancer chemotherapeutic drugs
WO2000045634A1 (en) Inositol derivatives for inhibiting superoxide anion production
EP1909800B1 (de) Acylglycerophospholipide zur behandlung von krebs-begleiterscheinungen
EP3606534B1 (en) Phospholipid derivatives and their use as medicaments
US9670238B1 (en) 5′-dibenzyl phosphates of 5-azacytidine or 2′-deoxy-5-azacytidine
CA2430190A1 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation
JPH02502096A (ja) 抗ウイルス化合物、そのような化合物を含む組成物及び治療方法
CN109963568A (zh) 由铂基化合物进行免疫记忆诱导
Moiseeva et al. Liposome formulations of combretastatin A4 and its 4-arylcoumarin analogue prodrugs: The antitumor effect in the mouse model of breast cancer
EP2114414B1 (en) Synthetic lipophilic inositol glycans for treatment of cancer and glucose-metabolism disorders
WO2024125676A1 (es) Variantes sintéticas del gangliósido ngcgm3 y su uso en el tratamiento del cáncer
CN101967168B (zh) 一种三萜皂甙衍生物及其制备方法和用途
JPH069663A (ja) リン脂質誘導体および細胞障害防御剤
Feng Probing phosphoinositide and isoprenoid binding proteins by photoaffinity labeling
CZ282139B6 (cs) Způsob výroby přípravku s dieteticko-preventivním a léčebným účinkem na bázi vaječných l-O-alkyl-2-acyl-fosfatidylethanolaminů
EP1421941A1 (en) Phospholipid derivatives having a polyhydroxylated aliphatic carbocycle
JP2006206607A (ja) 癌細胞内ヌクレアーゼ活性化剤

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191001

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20201123BHEP

Ipc: A61P 35/00 20060101ALI20201123BHEP

Ipc: A61K 31/685 20060101AFI20201123BHEP

Ipc: A61K 31/704 20060101ALI20201123BHEP

INTG Intention to grant announced

Effective date: 20201217

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMART BRAIN S.R.O.

Owner name: USTAV MOLEKULARNI GENETIKY AV CR, V.V.I.

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018017047

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1391720

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210615

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20210708

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3606534

Country of ref document: PT

Date of ref document: 20210716

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20210713

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1391720

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210512

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 37635

Country of ref document: SK

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20210401987

Country of ref document: GR

Effective date: 20210915

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20210512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210812

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2877647

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20211117

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E055171

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210812

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210912

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602018017047

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20220215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210912

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20220331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220329

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220331

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220329

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220331

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20230316

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20230314

Year of fee payment: 6

Ref country code: PT

Payment date: 20230301

Year of fee payment: 6

Ref country code: HU

Payment date: 20230310

Year of fee payment: 6

Ref country code: GR

Payment date: 20230317

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230412

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240319

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210512

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240319

Year of fee payment: 7

Ref country code: SK

Payment date: 20240308

Year of fee payment: 7

Ref country code: GB

Payment date: 20240318

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240304

Year of fee payment: 7

Ref country code: IT

Payment date: 20240321

Year of fee payment: 7

Ref country code: FR

Payment date: 20240315

Year of fee payment: 7